Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 in Healthy Volunteers
NCT07538466Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + linagliptin in diabetes mellitus (DM) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma and Area under the plasma concentration-time curve during dosing interval. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
dapagliflozin + linagliptin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07538466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538466.